Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study details of a Phase Ib/II study of Pembrolizumab with Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors.
    Difference
    0.1%
    Check dated 2024-06-06T14:19:19.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as a person's general health condition or prior treatments. This change likely pertains to medical and healthcare-related documentation.
    Difference
    50%
    Check dated 2024-05-22T20:57:42.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T23:01:05.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.